Acetamide, N-(4-hydroxyphenyl)- | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Acetamide, N-(4-hydroxyphenyl)-
US Exclusivities

PharmaCompass Sponsored Ads

Contact Supplier

Paracetamol

Contact Supplier

pharmacompass-1-m-2025-08-25

PharmaCompass Sponsored Ads

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Acetamide, N-(4-hydroxyphenyl)-

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

257 API Suppliers, 80 USDMF, 21 CEP/COS, 16 JDMF, 9 EU WC, 108 KDMF, 108 NDC API, 33 Listed Suppliers, $ API Reference Price

257 API Suppliers
80 USDMF
21 CEP/COS
16 JDMF
9 EU WC
108 KDMF
108 NDC API
33 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

370 Drugs in Development

370 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

2685 FDF Dossiers, 734 FDA Orange Book, 501 Europe, 292 Canada, 71 Australia, 402 South Africa, 685 Listed Dossiers

2685 FDF Dossiers
734 FDA Orange Book
501 Europe
292 Canada
71 Australia
402 South Africa
685 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SUPPOSITORY;RECTAL - 120MG, SUPPOSITORY;RECTAL - 325MG, SUPPOSITORY;RECTAL - 650MG, SUPPOSITORY;RECTAL - 80MG, CAPSULE;ORAL - 325MG;50MG;40MG;30MG, TABLET, EXTENDED RELEASE;ORAL - 325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 250MG;250MG;65MG, TABLET;ORAL - 325MG;37.5MG, SOLUTION;INTRAVENOUS - 1GM/100ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG;15MG, TABLET;ORAL - 300MG;30MG, TABLET;ORAL - 300MG;60MG, TABLET;ORAL - 325MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 325MG;50MG;40MG, TABLET;ORAL - 300MG;60MG

SUPPOSITORY;RECTAL - 120MG
SUPPOSITORY;RECTAL - 325MG
SUPPOSITORY;RECTAL - 650MG
SUPPOSITORY;RECTAL - 80MG
CAPSULE;ORAL - 325MG;50MG;40MG;30MG
TABLET, EXTENDED RELEASE;ORAL - 325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 250MG;250MG;65MG
TABLET;ORAL - 325MG;37.5MG
SOLUTION;INTRAVENOUS - 1GM/100ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 300MG;15MG
TABLET;ORAL - 300MG;30MG
TABLET;ORAL - 300MG;60MG
TABLET;ORAL - 325MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 325MG;50MG;40MG
TABLET;ORAL - 300MG;60MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Minakem, 1 Evonik, 13 Rochem International Inc, 32 SPI Pharma, 37 DKSH, 2 Pharm-RX Chemical, 14 Boai NKY Pharmaceuticals Ltd, 11 Gangwal Healthcare, 21 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Pfanstiehl, 1 Capital Farma, 14 Kirsch Pharma, 4 ACG Worldwide, 19 Actylis, 3 Aeon Procare, 2 Alcedo Pharmachem, 11 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 Ashland, 1 Avesta Pharma, 44 BASF, 8 Beneo, 2 Bioplus Life Sciences, 6 CD Formulation, 6 Clariant, 12 Corel Pharma Chem, 7 DFE Pharma, 2 Esteem Industries, 4 Finar, 17 Gangwal Chemicals, 2 Huzhou Sunflower Pharmaceutical, 5 Ideal Cures, 5 Ingredion Pharma Solutions, 26 Kerry, 4 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 27 Microlex e.U, 2 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 5 Novo Excipients, 5 Pharmatrans-Sanaq, 12 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 56 Roquette, 22 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 3 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 5 Silverline Chemicals, 1 Symrise, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 1 Valens Pharmachem, 5 Vasa Pharmachem, 3 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

127 Fillers, Diluents & Binders, 92 Thickeners and Stabilizers, 73 Solubilizers, 64 Coating Systems & Additives, 60 Taste Masking, 59 Topical, 55 Direct Compression, 54 Parenteral, 50 Disintegrants & Superdisintegrants, 45 Granulation, 39 Lubricants & Glidants, 38 Film Formers & Plasticizers, 35 Controlled & Modified Release, 28 Emulsifying Agents, 28 Chewable & Orodispersible Aids, 24 Rheology Modifiers, 18 Co-Processed Excipients, 17 Surfactant & Foaming Agents, 12 API Stability Enhancers, 9 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

127 Fillers, Diluents & Binders
92 Thickeners and Stabilizers
73 Solubilizers
64 Coating Systems & Additives
60 Taste Masking
59 Topical
55 Direct Compression
54 Parenteral
50 Disintegrants & Superdisintegrants
45 Granulation
39 Lubricants & Glidants
38 Film Formers & Plasticizers
35 Controlled & Modified Release
28 Emulsifying Agents
28 Chewable & Orodispersible Aids
24 Rheology Modifiers
18 Co-Processed Excipients
17 Surfactant & Foaming Agents
12 API Stability Enhancers
9 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 356 News #PharmaBuzz

2 Data Compilation #PharmaFlow
356 News #PharmaBuzz

GLOBAL SALES INFORMATION

94 US Medicaid Prescriptions, 403 Regulatory FDF Prices, 21 Annual Reports

94 US Medicaid Prescriptions
403 Regulatory FDF Prices
21 Annual Reports

MARKET PLACE

188 APIs, 95 FDF Dossiers

188 APIs
95 FDF Dossiers

PATENTS & EXCLUSIVITIES

41 US Patents, 2 US Exclusivities, 7 Health Canada Patents

41 US Patents
2 US Exclusivities
7 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 JP, 26 Others

1 EDQM
1 JP
26 Others

ANALYTICAL

2 BioAnalytical Methods, 8 Analytical Methods

2 BioAnalytical Methods
8 Analytical Methods

$ API Ref.Price (USD/KG) : 7 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

2 All

01 1AFT PHARMS US

02 1BAXTER HLTHCARE CORP

filter Product Reset all filters

2 All

01 1ACETAMINOPHEN

02 1ACETAMINOPHEN; IBUPROFEN

filter Exclusivity Expiration Date Reset all filters

2 All

01 12026-01-07

02 12026-03-01

filter Exclusivity Code Reset all filters

2 All

01 1NP

02 1PC

Granules Paracetamol

Product Main Page

AFT PHARMS US

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ACETAMINOPHEN; IBUPROFEN

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NP

Exclusivity Expiration Date

2026-03-01

Application Number

209471

Product Number

1

Exclusivity Details

01

AFT PHARMS US

ACETAMINOPHEN; IBUPROFEN

CPhI Korea

Not Confirmed

AFT PHARMS US

New Zealand

CPhI Korea

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ACETAMINOPHEN; IBUPROFEN

Exclusivity Code : NP

Exclusivity Expiration Date : 2026-03-01

Application Number : 209471

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

BAXTER HLTHCARE CORP

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ACETAMINOPHEN

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PC

Exclusivity Expiration Date

2026-01-07

Application Number

214331

Product Number

2

Exclusivity Details

02

BAXTER HLTHCARE CORP

CPhI Korea

Not Confirmed

BAXTER HLTHCARE CORP

U.S.A

CPhI Korea

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ACETAMINOPHEN

Exclusivity Code : PC

Exclusivity Expiration Date : 2026-01-07

Application Number : 214331

Product Number : 2

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!